Eric Lander, Government Accountability Office, Analyst, Donald Trump, Drugs, Growth hormone
Albert Bourla has some plans for Pfizer's huge Covid cash haul. Hint: 'Acquisitions are very much in the cards'
Today was Pfizer CEO Albert Bourla’s chance to relish the market success of its Covid vaccine and drug and what a fresh flow of $54 billion-plus from the pandemic franchise this year can do for the company. First on the list? The BD team is buckling down to pick up
Albert Bourla has some plans for Pfizer's huge Covid cash haul. Hint: 'Acquisitions are very much in the cards'
Today was Pfizer CEO Albert Bourla’s chance to relish the market success of its Covid vaccine and drug and what a fresh flow of $54 billion-plus from the pandemic franchise this year can do ...
We are sorry, we could not find the related article
If you are curious about Biotech and Career and Jobs
Please click on:
Subscribe to Biotech - Career and Jobs
Aduhelm reignites questions around ties between pharma and patient advocacy orgs
In the latest round of patient advocacy and the FDA, the drug reviewer approved Biogen and Eisai’s Alzheimer’s disease med Aduhelm over the advice of its own adcomm. Critics pointed to ...
BioWorld’s Top 10: Biggest newsmakers and trending stories of 2018
BioWorld's staff compiles the Top 10 (or so) most impactful biopharma stories and trends for 2018.
Biden and biotech: Science first
The November election now seems such a long time ago: It has, in fact, been less than three months, but that time has been filled with political and scientific catastrophes that will shape ...
Lilly's quick-launching Trulicity and Taltz stumbled this quarter. What gives?
Eli Lilly's top-launching new drugs Trulicity and Taltz didn't deliver as expected in the first quarter, and executives faced a grilling Tuesday on what they plan to do about it.